ARTICLE | Clinical News
MabThera rituximab regulatory update
January 30, 2012 8:00 AM UTC
The chimeric mAb against CD20 antigen is approved in the EU to treat NHL, chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL) and rheumatoid arthritis (RA). Biogen Idec and Roch...